• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials
scientific articles

Shared Decision Making for Hydroxyurea Treatment Initiation in Children With Sickle Cell Anemia

key information

source: Pediatric Blood & Cancer

year: 2015

authors: Lori E. Crosby, Lisa M. Shook, Russell E. Ware, William B. Brinkman


Clinical trials have demonstrated hydroxyurea’s efficacy in improving health outcomes for children with sickle cell anemia (SCA) who have medical complications. New NHLBI clinical guidelines will recommend offering hydroxyurea to young patients regardless of clinical severity. Shared decision making may be an effective approach for implementing this practice change. Decision aids that help patients/parents feel empowered to make this decision and help providers feel comfortable in discussing hydroxyurea as a preventive treatment may facilitate shared discussions between families and providers. We recommend six strategies providers can use to facilitate these discussions while decision aids and tools are being developed.

organization: Cincinnati Children's Hospital Medical Center, USA; University of Cincinnati College of Medicine, USA

DOI: 10.1002/pbc.25124

read more full text source